PubRank

Molecular and cellular therapies (Mol Cell Ther)

Journal PubWeight™ 41.02‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. 2015 1.32
2 Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. 2015 1.05
3 microRNA therapies in cancer. 2014 0.95
4 Therapeutic Opportunities for Targeting microRNAs in Cancer. 2014 0.94
5 The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. 2015 0.94
6 Targeting the Wnt pathways for therapies. 2014 0.93
7 The macrophage: a therapeutic target in HIV-1 infection. 2014 0.90
8 Gene therapy for cancer: present status and future perspective. 2014 0.87
9 Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. 2013 0.86
10 A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. 2014 0.85
11 Molecular and Cellular Therapies: New challenges and opportunities. 2013 0.83
12 Gene therapy for malignant glioma. 2014 0.83
13 Recruitment and retention of human autologous CD34+ CD117+ CD133+ bone marrow stem cells to infarcted myocardium followed by directed vasculogenesis: Novel strategy for cardiac regeneration. 2013 0.83
14 Albumin-based drug delivery: harnessing nature to cure disease. 2016 0.82
15 Role of solute carriers in response to anticancer drugs. 2014 0.81
16 Harnessing RNAi nanomedicine for precision therapy. 2014 0.81
17 Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells. 2014 0.81
18 Directed cardiomyogenesis of autologous human induced pluripotent stem cells recruited to infarcted myocardium with bioengineered antibodies. 2014 0.81
19 Strategic internal covalent cross-linking of TNF produces a stable TNF trimer with improved TNFR2 signaling. 2015 0.81
20 Neural stem cells: ready for therapeutic applications? 2014 0.80
21 MiR-223 regulates the differentiation of immature neurons. 2014 0.80
22 Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation. 2014 0.80
23 Low pH of interstitial fluid around hippocampus of the brain in diabetic OLETF rats. 2014 0.80
24 Stem cell in alternative treatments for brain tumors: potential for gene delivery. 2014 0.79
25 Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment. 2014 0.79
26 Human lung telocytes could promote the proliferation and angiogenesis of human pulmonary microvascular endothelial cells in vitro. 2014 0.78
27 Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules. 2016 0.78
28 Advances toward regenerative medicine in the central nervous system: challenges in making stem cell therapy a viable clinical strategy. 2014 0.78
29 MicroRNAs: short non-coding players in cancer chemoresistance. 2014 0.78
30 Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy. 2014 0.78
31 Improvements in biomaterial matrices for neural precursor cell transplantation. 2014 0.77
32 Adoptive T-cell therapy for Leukemia. 2014 0.77
33 Genome-wide analysis of primary peripheral blood mononuclear cells from HIV + patients-pre-and post- HAART show immune activation and inflammation the main drivers of host gene expression. 2014 0.76
34 Polymeric nanocarriers for the treatment of systemic iron overload. 2015 0.76
35 Making sense of how HIV kills infected CD4 T cells: implications for HIV cure. 2014 0.76
36 Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies? 2013 0.76
37 Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach. 2015 0.76
38 Aptamer technology for tracking cells' status & function. 2014 0.76
39 Magnetic nanoparticles for oligodendrocyte precursor cell transplantation therapies: progress and challenges. 2014 0.76
40 Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities? 2013 0.75
41 Platelet dysfunction in injured patients. 2014 0.75
42 Relevance of Wnt signaling for osteoanabolic therapy. 2014 0.75
43 The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia. 2016 0.75
44 Application of circulating tumor cells scope technique on circulating tumor cell research. 2014 0.75
45 Apixaban for oral antithrombotic therapy: is a new era coming? 2014 0.75
46 Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma. 2015 0.75
47 A brief perspective on neural cell therapy. 2014 0.75
48 "Much ado to achieve nothing: prospects for curing HIV infection". 2014 0.75
49 A prospective, randomized, three arm, open label study comparing the safety and efficacy of PP110, a novel treatment for hemorrhoids to preparation-H® maximum strength cream in the treatment of grade 2-3 hemorrhoids. 2015 0.75
50 Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. 2014 0.75
Next 50